相关实验视频

Updated: Jan 15, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

在EGFR突变NSCLC中,ACTN4基因扩增和阿克宁-4蛋白表达对奥西默提尼布有效性的研究

Takehiro Tozuka¹, Rintaro Noro¹, Yutaka Naito²

¹Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

|October 11, 2025

概括

动氨酸-4蛋白表达和基因放大与用 osimertinib 治疗表皮生长因子受体突变非小细胞肺癌患者的治疗结果较差有关. 这些发现确定了预测治疗反应的潜在生物标志物.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

动氨酸-4 (ACTN4) 是一种与癌症进展相关的动氨酸捆绑蛋白.
奥西默提尼布是一种针对表皮生长因子受体突变非小细胞肺癌 (NSCLC) 的向疗法.
在用 osimertinib 治疗的 NSCLC 中,ACTN4 的预后作用尚不清楚.

研究的目的:

调查ACTN4放大,动氨酸-4蛋白表达和EGFR突变NSCLC中 osimertinib疗效之间的关联.
为了确定潜在的生物标志物来预测对第一线 osimertinib 治疗的治疗反应.

主要方法:

对63名EGFR突变NSCLC患者的回顾性分析,这些患者接受了第一线 osimertinib.
免疫组织化学 (IHC) 对于在预处理瘤组织上的动素-4蛋白表达.
光在位杂交 (FISH) 以评估在IHC阳性病例中的ACTN4放大.

主要成果:

在63名患者中,在33名患者中观察到Actinin-4 IHC阳性.
与阴性病例相比,Actinin-4 IHC阳性患者的无进展生存期 (PFS) 和总生存期 (OS) 显著较短.
在33例IHC阳性病例中的4例中,FISH发现了ACTN4放大,在这些患者中观察到数量较短的PFS和OS.

结论:

在EGFR突变NSCLC中,ACTN4放大和提升的动因素-4蛋白表达与 osimertinib 疗效较差有关.
ACTN4状态可以作为对 osimertinib 治疗结果的预后生物标志物.
需要进一步的研究来验证这些发现,并探索针对ACTN4.4的治疗策略.

关键词:

在ACTN4中,ACTN4就是ACTN4.欧洲农业基金会 (EGFR) 是一个基金.这种药物是actinin-4的.非小细胞肺癌的肺癌.奥西米尔丁尼布 (osimertinib) 是一种

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Actin Polymerization and Cell Motility

Actin Polymerization and Cell Motility

Actin is a family of globular proteins that are highly abundant in eukaryotic cells. It makes up approximately 1-5% of total cell protein concentration. Actin monomers polymerize to form a complex network of polarized filaments, the actin cytoskeleton, that plays a crucial role in many cellular processes, including cell motility, division, endocytosis, and metastasis of cancer cells.
Actin cytoskeleton dynamics can produce pushing, pulling, and resistance forces that help the cell to migrate....

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...